Advances in HIV medication, its window of detection and its transmission risk within the last decade have led to an updated ...

HIV pre-exposure prophylaxis (PrEP) is a prevention strategy which includes the regular or event-driven use of antiretroviral medication to prevent HIV infection in adults. Several clinical trials ...

If the source person's HIV screening test result is negative but there has been a risk for HIV exposure in the previous 6 weeks, plasma HIV RNA testing of the source person is also recommended. In ...

The CDC, on behalf of the U.S. Public Health Service, has released the 2025 Guidelines for managing occupational exposure to HIV and postexposure prophylaxis (PEP), published in Infection Control & ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

There is growing evidence that pre-exposure prophylaxis (PrEP) prevents HIV acquisition. However, in the United States, approximately only 4% of people who could benefit from PrEP are currently ...

Subdermal delivery of antiretrovirals shows promise in early trials Researchers at the University of California, San Francisco, have found that pre-exposure prophylaxis can be effective in preventing ...

HIV-1 infection remains a major public health problem, with an estimated 38.4 million people living with HIV and 1.5 million new HIV infections reported worldwide in 2021. The risk of HIV infection ...

• If all of these services are not available, clinicians should assess the exposure and initiate nPEP when indicated according to the criteria and recommendations in these guidelines. The patient ...